Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-α on endothelial cells

Journal of Hypertension

Volumn 17, Issue 12 SUPPL., 1999, Pages 1837-1841

  Cominacini, Luciano ^a,c   Pasini, Anna Fratta ^a   Pastorino, Antonio M ^a   Garbin, Ulisse ^a   Davoli, Anna ^a   Rigoni, Anna ^a   Campagnola, Mario ^a   Tosetti, Maria L ^a   Rossato, Paolo ^b   Gaviraghi, Giovanni ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b GLAXOSMITHKLINE   (United States)

^c OSPEDALE POLICLINICO   (Italy)

Author keywords

Adhesion molecules; Dihydropyridines; Human umbilical vein endothelial cells; Low density lipoprotein; Tumour necrosis factor

Indexed keywords

AMLODIPINE; CELL ADHESION MOLECULE; DIHYDROPYRIDINE DERIVATIVE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LACIDIPINE; LERCANIDIPINE; LOW DENSITY LIPOPROTEIN; NIFEDIPINE; NIMODIPINE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIOXIDANT ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIPOPHILICITY; MASS SPECTROMETRY; PRIORITY JOURNAL; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

EID: 0033506641     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917121-00009     Document Type: Conference Paper

References (42)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809.
2. Haller H. Endothelial function. General considerations. Drugs 1997; 53 (Suppl. 1):1-10.
3. Simionescu M, Simionescu N. Functions of the endothelial cell surface. Ann Rev Physiol 1986; 48:279-304.
4. Scharf RE, Harker LA. Thrombosis and atherosclerosis: regulatory role of interactions among blood components and endothelium. Blut 1987; 55:131-144.
5. Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosa M, Osborn L, et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood 1990; 76:965-970.
6. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant MCP-1/JE. Am J Pathol 1990; 136:1229-1233.
7. Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell 1990; 62:3-6.
8. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner, JA. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest 1993; 92:471-478.
9. Hahne M, Jager U, Isenmann S, Hallmann R, Vestweber D. Five tumor necrosis factor-inducible cell adhesion mechanisms on the surface of mouse endothelioma cells mediate the binding of leukocytes. J Cell Biol 1993; 121:655-664.
10. Di Corleto PE, Chisolm GM. Participation of the endothelium in the development of the atherosclerotic plaque. Prog Lipid Res 1986; 25:365-374.
11. Faggiotto A, Ross R, Harker L. Studies of hypercholesterolemia in nonhuman primate: I. Changes that lead to fatty streak formation. Arteriosclerosis 1984; 4:323-340.
12. Gerrity G. The role of monocyte in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 1981 ; 103:181-190.
13. Henry PD, Bentley KI. Suppression of atherosclerosis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest 1981; 68:1366-1369.
14. Bernini F, Catapano AL, Corsini A, Fumagalli R, Paoletti R. Effect of calcium antagonists on lipids and atherosclerosis. Am J Cardiol 1989; 64:1291-1341.
15. Henry PD. Atherogenesis, calcium and calcium antagonists. Am J Cardiol 1990; 66:31-61.
16. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW, and the INTACT group investigators. Retardation of angiographic progression of coronary artery disease by nifedipine. Results from the International Nifedipine Trial on Anti-atherosclerotic therapy (INTACT). Lancet 1990; 335:1109-1113.
17. Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary artery disease. Part 2, short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-839.
18. Zanchetti A. Antiatherosclerotic effects of antihypertensive drugs:recent evidence and ongoing trials. Clin Exp Hypertension 1996; 18:489-499.
19. Zanchetti A. The antiatherogenetic effects of antihypertensive drugs: experimental and clinical evidence. Clin Exp Hypertens 1992; A14:307-331.
20. Nayler WG. Review of preclinical data of calcium channel blockers and atherosclerosis. J Cardiovasc Pharmacol 1999; 33 (Suppl.2):S7-S11.
21. Himmel HM, Whorton AR, Strauss HC. Intracellular calcium, currents, and stimulus-response coupling in endothelial cells. Hypertension 1993; 21:112-127.
22. Haller H, Schaper D, Ziegler W, Philipp S, Kuhlmann M, Distler A, et al. Low-density lipoprotein induces vascular adhesion molecule expression on human endothelial cells. Hypertension 1995; 25 (1):511-516.
23. van Amsterdam FTM, Roveri A, Maiorino M, Ratti E, Ursini F. Lacidipine: a dihydropyridine calcium antagonist with antioxidant activity. Free Rad Biol Med 1992; 12:183-187.
24. Cominacini L, Garbin U, Fratta Pasini A, Paulon T, Davoli A, Campagnola M, et al. Lacidipine inhibits the activation of the transcription factor NF-kappa B and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertension 1997; 15:1633-1639.
25. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. J Clin Invest 1973; 52:2745-2752.
26. Smith CW, Marlin SD, Rothlein R, Toman C, Anderson DC. Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. J Clin Invest 1989; 83:2008-2017.
27. Landegren U. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase: application to detection of lymphokines and cell surface antigens. J Immunol Methods 1984; 67:379-385.
28. Havel RJ, Eder MA, Bragdon JM. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34:1345-1353.
29. Cominacini L, Garbin U, Fratta Pasini A, Davoli A, Campagnola M, Contessi GB, et al. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Rad Biol Med 1997; 22:117-127.
30. Pang DC, Sperelakis N. Uptake of calcium antagonistic drugs into muscles as related to their lipid solubilities. Biochem Pharmacol 1984; 33:821-826.
31. van Zwieten P. The pharmacological properties of lipophilic calcium antagonists. Blood Press Suppl 1998; 2:5-9.
32. Tulenko TN, Brown J, Laury-Kleintop L, Khan M, Walter MF, Mason RP. Atheroprotection with amlodipine: cells to lesions and the PREVENT trial. J Cardiovasc Pharmacol 1999; 33 (Suppl.):S17-S22.
33. Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T. Functional analysis of the human vascular cell adhesion molecule-1 promoter. J Exp Med 1992; 176:1583-1593.
34. Voraberger G, Schafer R, Strotowa C. Cloning of the human gene for intercellular adhesion molecule 1 and analysis of its 5′-regulatory region. J Immunol 1991; 147:2777-2786.
35. Iademarco MF, McQuillan JJ, Rosen GD, Dean DC. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J Biol Chem 1992; 267:16323-16329.
36. Lenardo MJ, Baltimore D. NF-kB: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58:227-229.
37. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kB transcription factor and HIV-1. EMBO J 1991; 10:2247-2258.
38. Ghosh S, Baltimore D. Activation in vitro of NF-kB by phosphorylation of its inhibitor IkB. Nature 1990; 344:678-682.
39. Henkel T, Mackleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baeuerle PA. Rapid proteolysis of IkB-alpha is necessary for activation of transcription factor NF-kB. Nature 1993; 365:182-185.
40. Orekhov AN, Tertov VV, Sobenin IA, Akhmedzhanov NM, Pivovarova EM. Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. Int J Cardiol 1997; 62 (Suppl. 2):S67-S77.
41. Chen L, Haught WH, Yang B, Saldeen TG, Parthasarathy S, Mehta JL. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997; 30 (2):569-575.
42. Cominacini L, Garbin U, Fratta Pasini A, Davoli A, Campagnola M, Pastorino AM, et al. Oxidized LDL increases the production of intracellular reactive oxigen species in endothelial cells: inhibitory effect of lacidipine. J Hypertension 1998; 16:1913-1919.